NCT04232969View on ClinicalTrials.gov

Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

194

Participants

Timeline

Start Date

January 20, 2020

Primary Completion Date

February 24, 2024

Study Completion Date

July 31, 2024

Conditions

Parkinson's Disease

Interventions

DRUG

Exenatide extended release 2mg (Bydureon)

Subcutaneous Injection

Trial Locations (1)

Unknown

University College London Hospital, London

All Listed Sponsors

lead

University College, London

OTHER